[go: up one dir, main page]

WO2025132910A3 - Cell-free production method and uses - Google Patents

Cell-free production method and uses

Info

Publication number
WO2025132910A3
WO2025132910A3 PCT/EP2024/087582 EP2024087582W WO2025132910A3 WO 2025132910 A3 WO2025132910 A3 WO 2025132910A3 EP 2024087582 W EP2024087582 W EP 2024087582W WO 2025132910 A3 WO2025132910 A3 WO 2025132910A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
cell
target polypeptide
poi
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/087582
Other languages
French (fr)
Other versions
WO2025132910A2 (en
Inventor
Mats Anders LUNDGREN
Wouter Simon Petrus Jong
Hendrik Bart VAN DEN BERG VAN SAPAROEA
Natascha Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abera Bioscience AB
Original Assignee
Abera Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abera Bioscience AB filed Critical Abera Bioscience AB
Publication of WO2025132910A2 publication Critical patent/WO2025132910A2/en
Publication of WO2025132910A3 publication Critical patent/WO2025132910A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates to the field of cell-free protein or polypeptide production for the purpose of producing a polypeptide of interest (POI) which comprises a moiety, which is a target polypeptide whereof production is desired. The target polypeptide is linked to a coupling peptide which binds to a complementary peptide which is fused to an autotransporter fusion protein which is displayed on the outer surface of a vesicle such that the synthesized POI is coupled to said vesicle via isopeptide bond. Furthermore, the disclosure relates to compositions comprising such a target polypeptide moiety, which are amenable to use in therapeutic applications and/or biomedical applications.
PCT/EP2024/087582 2023-12-22 2024-12-19 Cell-free production method and uses Pending WO2025132910A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23219975.2 2023-12-22
EP23219975 2023-12-22

Publications (2)

Publication Number Publication Date
WO2025132910A2 WO2025132910A2 (en) 2025-06-26
WO2025132910A3 true WO2025132910A3 (en) 2025-07-31

Family

ID=89430118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/087582 Pending WO2025132910A2 (en) 2023-12-22 2024-12-19 Cell-free production method and uses

Country Status (1)

Country Link
WO (1) WO2025132910A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200377556A1 (en) * 2017-10-25 2020-12-03 Abera Bioscience Ab Display of heterologous molecules on bacterial cells and membrane vesicles
US20220235395A1 (en) * 2016-11-11 2022-07-28 Bio-Rad Laboratories, Inc. Methods for processing nucleic acid samples
US20230083394A1 (en) * 2021-08-25 2023-03-16 Cornell University Methods and compositions for docking biotinylated antigens on the exterior of bacterial outer membrane vesicles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220235395A1 (en) * 2016-11-11 2022-07-28 Bio-Rad Laboratories, Inc. Methods for processing nucleic acid samples
US20200377556A1 (en) * 2017-10-25 2020-12-03 Abera Bioscience Ab Display of heterologous molecules on bacterial cells and membrane vesicles
US20230083394A1 (en) * 2021-08-25 2023-03-16 Cornell University Methods and compositions for docking biotinylated antigens on the exterior of bacterial outer membrane vesicles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H BART VAN DEN BERG VAN SAPAROEA ET AL: "Display of Recombinant Proteins on Bacterial Outer Membrane Vesicles by Using Protein Ligation", vol. 84, no. 8, 9 February 2018 (2018-02-09), pages 1 - 17, XP055530760, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881043/pdf/e02567-17.pdf> [retrieved on 20181206], DOI: 10.1128/AEM *

Also Published As

Publication number Publication date
WO2025132910A2 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
US11364301B2 (en) Method of producing an immunoligand/payload conjugate
CA2380569C (en) Chimeric polypeptides, method for production and uses thereof
CN102762591A (en) Fibronectin based scaffold domain proteins that bind il-23
WO2021222762A3 (en) Activatable il2 composition and methods of use
Akbari et al. Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli
KR102357604B1 (en) A super-universal method for presenting cyclic peptides to protein structures
WO2021072129A3 (en) Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2025132910A3 (en) Cell-free production method and uses
Zheng et al. An enzyme‐cleavable solubilizing‐tag facilitates the chemical synthesis of mirror‐image proteins
CN104862328A (en) Preparation method of recombinant adalimumab Fab fragment in escherichia coli
JP7693553B2 (en) Protection of SpyTag-containing periplasmic fusion proteins from protease TSP and OMPT degradation
CN105143451B (en) Means and methods for expressing authentic human epidermal growth factor and/or basic fibroblast growth factor in the cytoplasm and/or culture medium of E.coli
CA2076320A1 (en) Process for producing peptide
PL238516B1 (en) Method for obtaining a modified polypeptide
Jiang et al. Functional expression and characterization of an acidic actinoporin from sea anemone Sagartia rosea
US5047333A (en) Method for the preparation of natural human growth hormone in pure form
JP2025510888A (en) Improving the efficiency of PAL-catalyzed protein ligation by a cascade enzymatic scheme
Huang et al. Human epidermal growth factor excreted by recombinant Escherichia coli K-12 has the correct N-terminus and is fully bioactive
JPWO2014175305A1 (en) Peptide-presenting protein and peptide library using the same
Busch et al. Specific N-terminal protein labelling: use of FMDV 3C pro protease and native chemical ligation
AU2016327453A1 (en) Generation of peptides
EP3218472B1 (en) Tag removal from proteins expressed in pro- and eukaryotic hosts
Goulatis et al. Impacts of the− 1 amino acid on yeast production of protein‐intein fusions
WO2019046446A3 (en) Compositions and methods using methanotrophic s-layer proteins for expression of heterologous proteins
US20230103563A1 (en) Split ch2 domains

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24834395

Country of ref document: EP

Kind code of ref document: A2